nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisinopril—ACE2—nephron—nephrolithiasis	0.0875	0.254	CbGeAlD
Lisinopril—ACE—renal artery—nephrolithiasis	0.0818	0.238	CbGeAlD
Lisinopril—Coxalgia—Hydrochlorothiazide—nephrolithiasis	0.0597	0.104	CcSEcCtD
Lisinopril—Knee pain—Hydrochlorothiazide—nephrolithiasis	0.0528	0.0916	CcSEcCtD
Lisinopril—Dry cough—Hydrochlorothiazide—nephrolithiasis	0.0322	0.0558	CcSEcCtD
Lisinopril—Pain in arm—Hydrochlorothiazide—nephrolithiasis	0.0303	0.0526	CcSEcCtD
Lisinopril—ACE—nephron—nephrolithiasis	0.0286	0.0831	CbGeAlD
Lisinopril—ACE—urine—nephrolithiasis	0.023	0.0667	CbGeAlD
Lisinopril—ACE2—nephron tubule—nephrolithiasis	0.0189	0.0549	CbGeAlD
Lisinopril—Shoulder pain—Hydrochlorothiazide—nephrolithiasis	0.0185	0.032	CcSEcCtD
Lisinopril—ACE2—renal system—nephrolithiasis	0.0172	0.0499	CbGeAlD
Lisinopril—ACE2—kidney—nephrolithiasis	0.0166	0.0482	CbGeAlD
Lisinopril—ACE2—cortex of kidney—nephrolithiasis	0.0162	0.047	CbGeAlD
Lisinopril—Atrioventricular block complete—Hydrochlorothiazide—nephrolithiasis	0.0142	0.0247	CcSEcCtD
Lisinopril—Leg pain—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0187	CcSEcCtD
Lisinopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC3A1—nephrolithiasis	0.00952	0.12	CbGpPWpGaD
Lisinopril—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.00887	0.0154	CcSEcCtD
Lisinopril—SLC15A1—nephron tubule—nephrolithiasis	0.00862	0.025	CbGeAlD
Lisinopril—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00809	0.014	CcSEcCtD
Lisinopril—SLC15A1—renal system—nephrolithiasis	0.00783	0.0228	CbGeAlD
Lisinopril—SLC15A1—kidney—nephrolithiasis	0.00757	0.022	CbGeAlD
Lisinopril—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.00723	0.0125	CcSEcCtD
Lisinopril—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.0069	0.012	CcSEcCtD
Lisinopril—Ventricular fibrillation—Hydrochlorothiazide—nephrolithiasis	0.0065	0.0113	CcSEcCtD
Lisinopril—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.00634	0.011	CcSEcCtD
Lisinopril—ACE—nephron tubule—nephrolithiasis	0.00618	0.0179	CbGeAlD
Lisinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A6—nephrolithiasis	0.00613	0.0771	CbGpPWpGaD
Lisinopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A9—nephrolithiasis	0.00598	0.0752	CbGpPWpGaD
Lisinopril—Jaundice cholestatic—Hydrochlorothiazide—nephrolithiasis	0.00566	0.00982	CcSEcCtD
Lisinopril—ACE—renal system—nephrolithiasis	0.00562	0.0163	CbGeAlD
Lisinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC3A1—nephrolithiasis	0.00561	0.0705	CbGpPWpGaD
Lisinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A3—nephrolithiasis	0.00561	0.0705	CbGpPWpGaD
Lisinopril—ACE—kidney—nephrolithiasis	0.00543	0.0158	CbGeAlD
Lisinopril—Gout—Hydrochlorothiazide—nephrolithiasis	0.00533	0.00924	CcSEcCtD
Lisinopril—ACE—cortex of kidney—nephrolithiasis	0.00529	0.0154	CbGeAlD
Lisinopril—Vasculitis—Hydrochlorothiazide—nephrolithiasis	0.0051	0.00884	CcSEcCtD
Lisinopril—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00503	0.00874	CcSEcCtD
Lisinopril—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00497	0.00863	CcSEcCtD
Lisinopril—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00848	CcSEcCtD
Lisinopril—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00483	0.00838	CcSEcCtD
Lisinopril—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.0047	0.00815	CcSEcCtD
Lisinopril—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00443	0.00768	CcSEcCtD
Lisinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC34A1—nephrolithiasis	0.00425	0.0535	CbGpPWpGaD
Lisinopril—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00417	0.00724	CcSEcCtD
Lisinopril—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00415	0.0072	CcSEcCtD
Lisinopril—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00411	0.00714	CcSEcCtD
Lisinopril—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00707	CcSEcCtD
Lisinopril—Haemolytic anaemia—Hydrochlorothiazide—nephrolithiasis	0.004	0.00694	CcSEcCtD
Lisinopril—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.00396	0.00688	CcSEcCtD
Lisinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A1—nephrolithiasis	0.00395	0.0497	CbGpPWpGaD
Lisinopril—Injury—Hydrochlorothiazide—nephrolithiasis	0.00393	0.00682	CcSEcCtD
Lisinopril—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00389	0.00676	CcSEcCtD
Lisinopril—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00381	0.00661	CcSEcCtD
Lisinopril—Renal impairment—Hydrochlorothiazide—nephrolithiasis	0.00379	0.00658	CcSEcCtD
Lisinopril—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.00372	0.00645	CcSEcCtD
Lisinopril—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00363	0.00629	CcSEcCtD
Lisinopril—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.00361	0.00627	CcSEcCtD
Lisinopril—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00622	CcSEcCtD
Lisinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A9—nephrolithiasis	0.00352	0.0443	CbGpPWpGaD
Lisinopril—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.00349	0.00605	CcSEcCtD
Lisinopril—Ataxia—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00589	CcSEcCtD
Lisinopril—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00338	0.00587	CcSEcCtD
Lisinopril—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.0033	0.00572	CcSEcCtD
Lisinopril—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00326	0.00566	CcSEcCtD
Lisinopril—Toxic epidermal necrolysis—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00564	CcSEcCtD
Lisinopril—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00325	0.00564	CcSEcCtD
Lisinopril—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.0032	0.00555	CcSEcCtD
Lisinopril—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00312	0.00542	CcSEcCtD
Lisinopril—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00306	0.00531	CcSEcCtD
Lisinopril—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00304	0.00528	CcSEcCtD
Lisinopril—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00506	CcSEcCtD
Lisinopril—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00292	0.00506	CcSEcCtD
Lisinopril—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00503	CcSEcCtD
Lisinopril—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00287	0.00499	CcSEcCtD
Lisinopril—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00285	0.00494	CcSEcCtD
Lisinopril—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00493	CcSEcCtD
Lisinopril—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00282	0.00489	CcSEcCtD
Lisinopril—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00486	CcSEcCtD
Lisinopril—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00276	0.00479	CcSEcCtD
Lisinopril—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00476	CcSEcCtD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00274	0.0345	CbGpPWpGaD
Lisinopril—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00274	0.00475	CcSEcCtD
Lisinopril—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.00273	0.00473	CcSEcCtD
Lisinopril—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.00273	0.00473	CcSEcCtD
Lisinopril—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00271	0.00471	CcSEcCtD
Lisinopril—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0027	0.00469	CcSEcCtD
Lisinopril—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00267	0.00463	CcSEcCtD
Lisinopril—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00265	0.0046	CcSEcCtD
Lisinopril—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00262	0.00455	CcSEcCtD
Lisinopril—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00261	0.00453	CcSEcCtD
Lisinopril—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00451	CcSEcCtD
Lisinopril—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00254	0.00441	CcSEcCtD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00251	0.0315	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00251	0.0315	CbGpPWpGaD
Lisinopril—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00435	CcSEcCtD
Lisinopril—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.0025	0.00433	CcSEcCtD
Lisinopril—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00248	0.0043	CcSEcCtD
Lisinopril—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00246	0.00427	CcSEcCtD
Lisinopril—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00236	0.0041	CcSEcCtD
Lisinopril—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00233	0.00404	CcSEcCtD
Lisinopril—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00402	CcSEcCtD
Lisinopril—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00223	0.00387	CcSEcCtD
Lisinopril—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00221	0.00383	CcSEcCtD
Lisinopril—ABCB1—nephron tubule—nephrolithiasis	0.00217	0.00632	CbGeAlD
Lisinopril—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00217	0.00377	CcSEcCtD
Lisinopril—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00214	0.00372	CcSEcCtD
Lisinopril—Tension—Hydrochlorothiazide—nephrolithiasis	0.00213	0.0037	CcSEcCtD
Lisinopril—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00213	0.0037	CcSEcCtD
Lisinopril—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00211	0.00366	CcSEcCtD
Lisinopril—Back pain—Hydrochlorothiazide—nephrolithiasis	0.0021	0.00365	CcSEcCtD
Lisinopril—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00209	0.00363	CcSEcCtD
Lisinopril—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00205	0.00356	CcSEcCtD
Lisinopril—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00204	0.00354	CcSEcCtD
Lisinopril—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00202	0.0035	CcSEcCtD
Lisinopril—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.00201	0.00349	CcSEcCtD
Lisinopril—Angioedema—Hydrochlorothiazide—nephrolithiasis	0.00199	0.00345	CcSEcCtD
Lisinopril—ABCB1—renal system—nephrolithiasis	0.00198	0.00574	CbGeAlD
Lisinopril—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00196	0.0034	CcSEcCtD
Lisinopril—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00339	CcSEcCtD
Lisinopril—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00338	CcSEcCtD
Lisinopril—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00195	0.00338	CcSEcCtD
Lisinopril—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00192	0.00333	CcSEcCtD
Lisinopril—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00332	CcSEcCtD
Lisinopril—ABCB1—kidney—nephrolithiasis	0.00191	0.00555	CbGeAlD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.0019	0.0239	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.0019	0.0239	CbGpPWpGaD
Lisinopril—Cough—Hydrochlorothiazide—nephrolithiasis	0.0019	0.00329	CcSEcCtD
Lisinopril—ABCB1—cortex of kidney—nephrolithiasis	0.00186	0.00541	CbGeAlD
Lisinopril—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00321	CcSEcCtD
Lisinopril—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00321	CcSEcCtD
Lisinopril—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00185	0.00321	CcSEcCtD
Lisinopril—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00184	0.0032	CcSEcCtD
Lisinopril—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00183	0.00317	CcSEcCtD
Lisinopril—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00181	0.00314	CcSEcCtD
Lisinopril—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00179	0.00311	CcSEcCtD
Lisinopril—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00308	CcSEcCtD
Lisinopril—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00177	0.00308	CcSEcCtD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00177	0.0222	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00177	0.0222	CbGpPWpGaD
Lisinopril—Shock—Hydrochlorothiazide—nephrolithiasis	0.00175	0.00303	CcSEcCtD
Lisinopril—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00174	0.00302	CcSEcCtD
Lisinopril—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00173	0.00301	CcSEcCtD
Lisinopril—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00172	0.00298	CcSEcCtD
Lisinopril—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00169	0.00294	CcSEcCtD
Lisinopril—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00166	0.00288	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00162	0.00281	CcSEcCtD
Lisinopril—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00161	0.00279	CcSEcCtD
Lisinopril—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00159	0.00277	CcSEcCtD
Lisinopril—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.00158	0.00275	CcSEcCtD
Lisinopril—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00158	0.00274	CcSEcCtD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00157	0.0198	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00156	0.0197	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00156	0.0197	CbGpPWpGaD
Lisinopril—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00156	0.00271	CcSEcCtD
Lisinopril—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00154	0.00268	CcSEcCtD
Lisinopril—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00153	0.00266	CcSEcCtD
Lisinopril—Pain—Hydrochlorothiazide—nephrolithiasis	0.00152	0.00263	CcSEcCtD
Lisinopril—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00152	0.00263	CcSEcCtD
Lisinopril—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00146	0.00254	CcSEcCtD
Lisinopril—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.00145	0.00252	CcSEcCtD
Lisinopril—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00141	0.00245	CcSEcCtD
Lisinopril—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00243	CcSEcCtD
Lisinopril—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.0014	0.00243	CcSEcCtD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00139	0.0175	CbGpPWpGaD
Lisinopril—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00131	0.00227	CcSEcCtD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00127	0.016	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00127	0.016	CbGpPWpGaD
Lisinopril—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00127	0.00221	CcSEcCtD
Lisinopril—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00126	0.00218	CcSEcCtD
Lisinopril—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00121	0.00211	CcSEcCtD
Lisinopril—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00117	0.00204	CcSEcCtD
Lisinopril—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00113	0.00196	CcSEcCtD
Lisinopril—Rash—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00194	CcSEcCtD
Lisinopril—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00112	0.00194	CcSEcCtD
Lisinopril—Headache—Hydrochlorothiazide—nephrolithiasis	0.00111	0.00193	CcSEcCtD
Lisinopril—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00105	0.00183	CcSEcCtD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000965	0.0121	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000965	0.0121	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000897	0.0113	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000897	0.0113	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.0008	0.0101	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.0008	0.0101	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000639	0.00804	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000528	0.00664	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000528	0.00664	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000471	0.00592	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000431	0.00542	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000431	0.00542	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000326	0.0041	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000326	0.0041	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000303	0.00382	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000303	0.00382	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00027	0.0034	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00027	0.0034	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000216	0.00272	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000187	0.00236	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000167	0.0021	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—APRT—nephrolithiasis	0.000142	0.00179	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000142	0.00179	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—AQP1—nephrolithiasis	0.000101	0.00127	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CHRM3—nephrolithiasis	9.16e-05	0.00115	CbGpPWpGaD
